Aptinyx

Aptinyx ROCE

Delisted

The Return on Capital Employed (ROCE) of Aptinyx (APTX) as of Oct 30, 2026 is -163.42 %. In the previous year, Return on Capital Employed (ROCE) was -78.66 % — a change of 107.76% (lower).

ROCE

-163.42 %

YoY

107.76%

Last updated:

In 2022, Aptinyx's return on capital employed (ROCE) was -163.42 %, a 107.76% increase from the -78.66 % ROCE in the previous year.

The Aptinyx ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2016
207.19 USD
Jan 1, 2017
81.15 USD
Jan 1, 2018
-36.76 USD
Jan 1, 2019
-58.84 USD
Jan 1, 2020
-34.79 USD
Jan 1, 2021
-78.66 USD
Jan 1, 2022
-163.42 USD
The Aptinyx ROCE history
YEARROCEYoY
-163.42 %+107.76%
-78.66 %+126.08%
-34.79 %-40.87%
-58.84 %+60.07%
-36.76 %-145.30%
81.15 %-60.83%
207.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptinyx Stock analysis

What does Aptinyx do? Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Aptinyx's Return on Capital Employed (ROCE)

Aptinyx's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Aptinyx's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Aptinyx's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Aptinyx’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Aptinyx stock

Return on Capital Employed (ROCE) of Aptinyx is -163.42 % in 2022.

Return on Capital Employed (ROCE) of Aptinyx changed from -78.66 % to -163.42 %, representing a 107.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Aptinyx since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Aptinyx with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Aptinyx

All Key Metrics — Aptinyx